The Mechanism of Sox4 Transcription in Regulation of Angiogenesis in Hepatocellular Carcinoma

SOX4 Activates CXCL12 in Hepatocellular Carcinoma Cells to Modulate Endothelial Cell Migration and Angiogenesis in Vivo

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04296058

Acronym

SOX4 in HCC

Enrollment

200

Registered

2020-03-05

Start date

2007-01-08

Completion date

2019-03-31

Last updated

2020-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Translational Research of SOX4 in Hepatocellular Carcinoma

Keywords

SOX4, angiogenesis, microvessel density

Brief summary

Two hundred HCC patients with partial hepatectomy were enrolled as a cohort for observational study. The inclusion criterion was intended curative hepatectomy for HCC patients by image analysis, and the exclusion criteria were unresectable disease, synchronous cancers, recurrent cancers, or distant metastasis. The study endpoint was 30 March 2019, and tumor staging was based on the 8th edition of the American Joint Committee on Cancer (AJCC) TNM staging system for HCC

Detailed description

To determine the role of SOX4 in tumor progression in patients with HCC, we examined SOX4 expression through immunohistochemistry (IHC) staining of 200 formalin-fixed and paraffin-embedded (FFPE) HCC specimens . The SOX4 high group of patients was associated with positive etiology of hepatitis B virus (P = 0.044), tumor size \>5 cm (P = 0.014), thrombus formation (P = 0.012), higher microvessel density (MVD) (P = 0.012) in tumor lesions, and distant metastasis (P \<0.001). Cox regression analysis showed that patients with elderly age (P \<0.001), higher ⍺-fetal protein (AFP) (P = 0.045), presence of cirrhosis (P = 0.008), and SOX4 high in tumor specimen (P = 0.042) were independent risk factors . The SOX4 high group performed significantly worse regarding overall survival (OS) (P = 0.043) and disease-free survival (DFS) (P = 0.019) based on the Kaplan-Meier analysis.

Interventions

OTHERmicrovessel density

the vessel numbers in high power field with Anti-CD31 staining in tumor specimen

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 85 Years

Healthy volunteers

Inclusion criteria

subjects with pathologic diagnosis of hepatocellular carcinoma and curative partial hepatectomies -

Exclusion criteria

history of different malignant disease, subject cannot be treated with curative surgery -

Design outcomes

Primary

Measure	Time frame	Description
Disease free survival (DFS)	a month	The length of time from curative hepatectomies and recurrence or mortality

Secondary

Measure	Time frame	Description
Overall survival	a month	The length of time from curative hepatectomies and still alive

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026